15P Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: A multicentre real-world study
Annals of Oncology · 2026-12 · 37 · S380
DOI: 10.1016/j.annonc.2026.08.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von M.V. Bonomo und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bonomo, M., Scagnoli, S., Pantano, F., Scafetta, R., Vici, P., Astone, A., Rossi, V., Paris, I., Orlandi, A., Fabi, A., Giordani, E., Fabbri, M., D'Auria, G., Pisegna, S., Alesini, D., Falbo, P., Bonadonna, C., Verrico, M., Bria, E., & Botticelli, A. (2026). 15P Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: A multicentre real-world study. Annals of Oncology, 37, S380. https://doi.org/10.1016/j.annonc.2026.08.024
Vancouver
Bonomo M, Scagnoli S, Pantano F, Scafetta R, Vici P, Astone A, et al. 15P Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: A multicentre real-world study. Annals of Oncology. 2026;37:S380. doi:10.1016/j.annonc.2026.08.024
BibTeX
@article{Bonomo2026,
author = {Bonomo, M.V. and Scagnoli, S. and Pantano, F. and Scafetta, R. and Vici, P. and Astone, A. and Rossi, V. and Paris, I. and Orlandi, A. and Fabi, A. and Giordani, E. and Fabbri, M.A. and D'Auria, G.D. and Pisegna, S. and Alesini, D. and Falbo, P.T. and Bonadonna, C. and Verrico, M. and Bria, E. and Botticelli, A.},
title = {15P Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: A multicentre real-world study},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S380},
doi = {10.1016/j.annonc.2026.08.024}
}
EUVIMED